Essential fatty acids in the treatment of dry eye

  • E.S. R
  • P.A. A
  • Rosenberg E
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Essential fatty acids (EFAs) play many important roles in human biology, affecting organ systems and cellular and intracellular function. Omega-3 and omega-6 EFAs are the precursors of eicosanoids, locally acting hormones involved in mediating inflammatory processes. It is largely via the production of these eicosanoids that the essential fatty acids influence human health and disease. In general, the omega-3 derived eicosanoids are anti-inflammatory while the n-6 pathway eicosanoids promote inflammation. To date, EFAs have been primarily studied with regard to systemic diseases, particularly cardiovascular disease. Currently, no dietary recommendations of EFAs for the prevention or treatment of eye disease exist. The majority of studies concerning EFAs and eye disease have focused on diseases of the retina. This article provides an overview of the current literature regarding EFAs and dry eye disease (DED). Eight studies were identified, including six randomized controlled trials. All the studies preliminarily confirmed that there is a relationship between EFA supplementation and improvement in DED. However, strong conclusions cannot be made yet because of limitations in the research reported. The role of essential fatty acids is an important topic that would benefit from a large, multicenter, randomized clinical trial powered to reach a conclusion regarding the efficacy of essential fatty acids in the treatment of dry eye disease.

Author-supplied keywords

  • *dry eye/dt [Drug Therapy]
  • *dry eye/th [Therapy]
  • *essential fatty acid/ct [Clinical Trial]
  • *essential fatty acid/dt [Drug Therapy]
  • *essential fatty acid/pd [Pharmacology]
  • Dietary Fats/therapeutic use
  • Dry Eye Syndromes/metabolism/ therapy
  • Essential/pharmacokinetics/ therapeut
  • Fatty Acids
  • Humans
  • Sjoegren syndrome/dt [Drug Therapy]
  • Treatment Outcome
  • alpha tocopherol/ct [Clinical Trial]
  • alpha tocopherol/dt [Drug Therapy]
  • arachidonic acid/ct [Clinical Trial]
  • blepharitis/dt [Drug Therapy]
  • clinical trial
  • docosahexaenoic acid/ct [Clinical Trial]
  • drug efficacy
  • drug inhibition
  • drug safety
  • fish oil/pd [Pharmacology]
  • fish oil/pr [Pharmaceutics]
  • gamma linolenic acid/dt [Drug Therapy]
  • heart infarction/dt [Drug Therapy]
  • heart infarction/th [Therapy]
  • human
  • hypertriglyceridemia/dt [Drug Therapy]
  • icosapentaenoic acid/ct [Clinical Trial]
  • keratoconjunctivitis/dt [Drug Therapy]
  • keratoconjunctivitis/th [Therapy]
  • linoleic acid/ct [Clinical Trial]
  • linoleic acid/dt [Drug Therapy]
  • medical literature
  • metabolism
  • nonhuman
  • omega 3 fatty acid/cb [Drug Combination]
  • omega 3 fatty acid/ct [Clinical Trial]
  • omega 3 fatty acid/dt [Drug Therapy]
  • omega 3 fatty acid/pd [Pharmacology]
  • omega 3 fatty acid/po [Oral Drug Administration]
  • omega 6 fatty acid/cb [Drug Combination]
  • omega 6 fatty acid/ct [Clinical Trial]
  • omega 6 fatty acid/dt [Drug Therapy]
  • omega 6 fatty acid/pd [Pharmacology]
  • omega 6 fatty acid/po [Oral Drug Administration]
  • placebo
  • protein function
  • retina macula age related degeneration/dt [Drug Th
  • retina macula age related degeneration/pc [Prevent
  • review
  • supplementation

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Rosenberg E.S.

  • Asbell P.A.

  • Elana S Rosenberg

  • Penny A Asbell

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free